NeoGraph Analytics
BiotechnologyNorth America2023 – 2032

Global Asia Pacific CRISPR Technology Market Size, Share and Trends Analysis

Asia Pacific CRISPR Technology market valued at $1.2B in 2023, projected to reach $4.7B by 2032 at a 16.5% CAGR.

Revenue, 2023

$1.2B

Forecast, 2032

$4.7B

CAGR, 2024-2032

16.5%

Report Coverage

North America

Code: asia-pacific-crispr-technology-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Executive Summary

The Asia Pacific CRISPR technology market was valued at USD 1.2 billion in 2023 and is projected to reach USD 4.7 billion by 2032, growing at a CAGR of 16.5%. The region accounts for approximately 32% of the global CRISPR market, driven by rapid adoption in China, Japan, and India. Key growth catalysts include expanding pharmaceutical R&D expenditure, government funding for gene editing research, and increasing applications in agriculture and clinical therapeutics. The therapeutics segment is expected to witness the highest growth, while agricultural applications remain the largest current revenue contributor. North America remains the dominant region globally, but Asia Pacific is the fastest-growing market. Strategic collaborations between global biotech firms and APAC research institutions are accelerating technology commercialization.

02

Key Highlights

1

Market valued at USD 1.2B in 2023, growing at 16.5% CAGR

2

North America leads with largest regional market share

3

Asia Pacific is the fastest-growing regional market

03

Market Overview

Market Context

The CRISPR Technology market is shaped by rapid technological innovation, shifting consumer preferences, and increasing regulatory focus on sustainability and compliance.

The Asia Pacific CRISPR technology market generated USD 1.2 billion in 2023 and is projected to grow at a 16.5% CAGR to reach USD 4.7 billion by 2032. China, Japan, and India are the key markets driving regional growth. The market is in a high-growth stage with increasing adoption across therapeutics, agriculture, and diagnostics.

Market Stage

High growth

Adoption Level

Growing

Key Trends

Rapid adoption of CRISPR-Cas9 in drug discovery pipelines across APAC pharmaceutical companiesGrowing investment in CRISPR-based agricultural biotechnology for crop improvementEmergence of advanced base editing and prime editing technologies in regional labsIncreasing government funding for genomics and gene editing research programs
04

Market Forecast & Data

Market Growth Forecast
2024-2032 · CAGR 16.5%

Base Year (2023)

$1.2B

Forecast (2032)

$4.7B

CAGR (2024-2032)

16.5%

Market size by year, 2024-2032, in USD Billion.
YearMarket size ($ Billion)
2023Base year$1.20B
2024$1.40B
2025$1.63B
2026$1.90B
2027$2.21B
2028$2.58B
2029$3.00B
2030$3.50B
2031$4.07B
2032$4.74B
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Forecast Analysis

The market is forecast to maintain robust growth through 2032, driven by expanding applications, new entrant investments, and emerging market adoption.

Regional Market Analysis
Market share and growth rate by region
Regional market analysis — market share, growth rate and largest market by region.
RegionMarket shareGrowth rateLargest market
North America40.0%12.5%United States
Europe28.0%10.8%Germany
Asia Pacific32.0%18.2%China

North America

#1
Share: 40.0%CAGR: 12.5%

Largest market: United States

Europe

#2
Share: 28.0%CAGR: 10.8%

Largest market: Germany

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
05

Market Dynamics

  • Rising pharmaceutical R&D investment across China, Japan, and India
  • Government funding for gene editing and genomics research programs
  • Growing demand for targeted therapeutics and precision agriculture
06

Market Segmentation

By Application
Market share distribution across 4 segments
By Application — market share by segment, in percent.
SegmentShare
Drug Discovery & DevelopmentTarget identification, validation, and preclinical therapeutic development using CRISPR screening.35.0%
Agriculture & Food ScienceCrop improvement, disease resistance, and yield enhancement through gene-edited plant varieties.25.0%
DiagnosticsCRISPR-based molecular diagnostic platforms including SHERLOCK and DETECTR systems.20.0%
Basic ResearchFundamental life sciences research, functional genomics, and disease modeling applications.20.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
By Product Type
Market share distribution across 4 segments
By Product Type — market share by segment, in percent.
SegmentShare
CRISPR Kits & ReagentsConsumable tools for gene editing research widely used in academic and industrial laboratories.45.0%
CRISPR TherapeuticsClinical and commercial gene therapy products developed using CRISPR editing platforms.25.0%
CRISPR ServicesContract-based gene editing services including cell line engineering and custom modifications.18.0%
CRISPR Software & DatabasesBioinformatics tools and platforms for guide RNA design, off-target prediction, and data analysis.12.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.

By End User

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Contract Research Organizations (CROs)
  • Hospitals & Clinics
07

Regional Analysis

1

North America

Lead: United States
CAGR: 12.5%Share: 40.0%

Dominant global market driven by established biotech ecosystem, strong IP portfolio, and clinical pipeline advancements.

2

Europe

Lead: Germany
CAGR: 10.8%Share: 28.0%

Significant research base with growing regulatory clarity supporting CRISPR therapeutic development.

3

Asia Pacific

Lead: China
CAGR: 18.2%Share: 32.0%

Fastest-growing region propelled by government funding, expanding biotech infrastructure, and rising R&D investments.

Country-Level Analysis

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Market share and growth rate by country
CountryShareGrowth
United States
38.0%
+12.5%
China
25.0%
+19.5%
Germany
14.0%
+10.8%
08

Competitive Landscape

C

CRISPR Therapeutics AG

Switzerland

Leader2.1B

Pioneering gene editing therapeutics developer with the first approved CRISPR therapy, Casgevy, and strong APAC partnerships.

A leading gene editing company developing transformative therapies using proprietary CRISPR-Cas9 technology with a strong APAC commercial presence.

E

Editas Medicine, Inc.

United States

Challenger850M

Clinical-stage biotechnology company advancing in vivo and ex vivo CRISPR genomic medicines with growing APAC collaborations.

A clinical-stage biotechnology company focused on developing best-in-class genomic medicines using its CRISPR-based editing platforms.

B

BGI Group

China

Follower1.5B

China-based genomics leader providing CRISPR research tools, gene editing services, and agricultural biotechnology solutions across APAC.

A global genomics research institution and technology provider with extensive CRISPR research capabilities and agricultural gene editing solutions.

09

Recent Developments

25
2025CRISPR Therapeutics

CRISPR Therapeutics receives regulatory approval for Casgevy in Japan, expanding its APAC market presence significantly.

24
2024BGI Group

BGI Group launches a CRISPR-based agricultural gene editing platform targeting Asia-Pacific crop markets.

10

Regulatory Landscape

Japan's Ministry of Health,
11

Research Methodology

Primary research

  • Expert interviews
  • Industry surveys

Secondary research

  • Industry reports
  • Company financials
  • Government databases

Validation: Triangulation method with cross-referencing multiple data sources

12

Strategic Takeaways

Investors

High-growth CRISPR Technology sector offers compelling entry opportunities

Operators

Focus on technology differentiation to capture market share

13

Frequently Asked Questions

Reports in the same field, each with its base-year figure and the growth rate it is published at.